![Targeted Cancer Therapies](https://stoyanovalab.org/wp-content/uploads/2023/02/11.jpg)
![Small molecular inhibitors.](https://stoyanovalab.org/wp-content/uploads/2023/02/1-300x300.jpg)
1) Small molecular inhibitors. The Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers including the discovery and testing of new therapeutic targets and new small molecule inhibitors. Currently the lab focuses on prostate, breast, lung cancer, and neuroblastoma.
![Small molecular inhibitor screening](https://stoyanovalab.org/wp-content/uploads/2023/02/2-300x300.jpg)
2) Small molecular inhibitor screening. The Stoyanova lab utilizes High-Throughput Screening (HTS) to identify new and selective small molecule inhibitors for metastatic epithelial cancers.
![Antibody-based therapies for advanced prostate, breast, lung, and other epithelial cancers](https://stoyanovalab.org/wp-content/uploads/2023/02/3-300x300.jpg)
3) Antibody-based therapies for advanced prostate, breast, lung, and other epithelial cancers. The Stoyanova lab develops and tests antibody-based strategies as targeted therapies. We also construct new antibody-drug conjugates as a therapeutic strategy to deliver toxic agents to the tumor sites.